Universitätsklinikum Düsseldorf

Itching in Atopic Dermatitis: Patient-and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany (2023) Weisshaar E, Bentz P, Apfelbacher C, Haufe E, Heinrich L, Heratizadeh A, Abraham S, et al. Journal article The CAM Model—Q&A with Experts (2023) Fischer D, Fluegen G, Garcia P, Ghaffari-Tabrizi-Wizsy N, Gribaldo L, Huang RYJ, Rasche V, et al. Journal article, Review article Impact of Anxiety During Hospitalization on the Clinical Outcome of Patients With Osteoporotic Thoracolumbar Vertebral Fracture (2023) Schwarz F, Klee E, Schenk P, Katscher S, Schnake KJ, Bäumlein M, Zimmermann V, et al. Journal article Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. (2023) Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, et al. Journal article Generelle Fraktur- und Osteoporoseprophylaxe: Fokus Sturz (2022) Thomasius F, Maus U, Niedhart C, Brabant T, Belavy D, Kühlein T Journal article Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akcetin L, et al. Journal article AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas (2022) Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, et al. Journal article Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort (2022) Freise NF, Gliga S, Fischer J, Lübke N, Lutterbeck M, Schöler M, Bölke E, et al. Journal article Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report (2022) von Stillfried S, Bülow RD, Röhrig R, Meybohm P, Boor P, Böcker J, Schmidt J, et al. Journal article Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution